V.A. MALIEVSKY^1, 2, S.S. ZHUKOV¹, E.P. PERVUSHINA², A.Zh. NURIAKHMETOVA², L.R. NURGALIEVA², E.D. SHAKIRYANOVA², A.A. KHASANOVA²

 ¹Bashkir State Medical University of the Ministry of Health of the Russian Federation, Ufa

²Republic Children’s Clinical Hospital, Ufa

 Contact details:

Malievsky V.A. — MD, Professor, Head of the Department of Hospital Pediatrics

Address: 3 Lenin St., Ufa, Russian Federation, 450008, tel.: +7 (347) 229-08-12, e-mail: vmalievsky@mail.ru

Juvenile arthritis is the group of the most common rheumatic diseases in children, with a long progressive course and development of disability [1]. The article presents a clinical case of systemic juvenile idiopathic arthritis (sJIA), complicated by resistance to a genetically engineered drug (GEBAs) — tocilizumab (TCZ). The presented clinical case shows the high efficiency and safety of canakinumab in the treatment of the systemic variant of JIA in a patient with a long duration of the disease (11 years), refractoriness to the combined basic antirheumatic therapy, and tocilizumab intolerance.
Key words: children, juvenile idiopathic arthritis, genetic engineering biological preparations, allergic reaction.

(For citation: Malievsky V.A., Zhukov S.S., Pervushina E.P., Nuriakhmetova A.Zh., Nurgalieva L.R., Shakiryanova E.D., Khasanova A.A. Clinical case of kanakinumab application in a patient with systemic juvenile idiopathic arthritis with tocylisumab inability. Practical Medicine. 2019. Vol. 17, № 5, P. 228-230)

REFERENCES

1. Petty R.E., Southwood T.R., Manners P., Baum J., Glass D.N., Goldenberg J., He X., Maldonado-Cocco J., Orozco-Alcala J., Prieur A.M., Suarez-Almazor M.E., Woo P. International League of Assotiations Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol, 2004, vol. 31 (2), pp. 390–392.
2. Alekseeva E.I., Lomakina O.L., Valieva S.I., Bzarova T.M. Review of international registries of patients with systemic juvenile idiopathic arthritis. Voprosy sovremennoy pediatrii, 2017, no. 16 (1), pp. 18–23 (in Russ.). doi: 10.15690/vsp.v16i1.1690
3. Malievskiy V.A. Yuvenil’nye artrity: epidemiologiya, mediko-sotsial’nye i ekonomicheskie posledstviya, kachestvo zhizni: avtoref. diss. … d-ra. med. nauk [Juvenile arthritis: epidemiology, medical, social and economic consequences, quality of life. Synopsis of dis. Dr med. sciences]. Moscow, 2006. 38 p.
4. De Benedetti F., Ruperto N., Brunner H. et al. A6: tapering and with drawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER Study. Arthritis Rheum, 2014, vol. 66, pp. S8–9. doi: 10.1002/art.38417
5. Ruperto N., Brunner H., Horneff G. Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1b antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study. Pediatr. Rheumatol, 2011, vol. 9 (1), p. 21.
6. Ruperto N., Brunner H.I., Quartier P., Constantin T., Wulffraat N., Horneff G. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med, 2012, vol. 367 (25), pp. 2396–2406.
7. Wulffraat N., Ruperto, N., Brunner, H., Oliveira, S. Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients. Pediatr. Rheumatol, 2014, vol. 12 (1), p. 68.
8. Ruperto N., Brunner H.I., Quartier P., Constantin T., Wulffraat N.M. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis, 2018, Dec, vol. 77 (12), pp. 1710–1719.